Long-term clinical outcomes of Zikaassociated Guillain-Barré syndrome
dc.contributor.author | Chang, Aileen Y. | |
dc.contributor.author | Lynch, Rebecca | |
dc.contributor.author | Martins, Karen | |
dc.contributor.author | Encinales, Liliana | |
dc.contributor.author | Cadena Bonfanti, Andrés Á. | |
dc.contributor.author | Pacheco, Nelly | |
dc.contributor.author | Reid, St. Patrick | |
dc.contributor.author | Lara Sarabia, Osvaldo E. | |
dc.contributor.author | González Torres, Henry J. | |
dc.contributor.author | Mejia Castillo, Stella | |
dc.contributor.author | Barrios Taborda, Onaldo | |
dc.contributor.author | Alarcon Gomez, Magda | |
dc.contributor.author | Guerra Duran, Brenda | |
dc.contributor.author | Martinez Giraldo, Victor | |
dc.contributor.author | Benitez Ospino, Angélica | |
dc.contributor.author | Porras, Alexandra | |
dc.contributor.author | Mendoza, Alejandro R. | |
dc.contributor.author | Mantus, Grace | |
dc.contributor.author | Li, Guangzhao | |
dc.contributor.author | Peng, Jin | |
dc.contributor.author | Kamalapathy, Priyanka | |
dc.contributor.author | Avendaño Echavez, Lil G. | |
dc.contributor.author | Dowd, Kimberly A. | |
dc.contributor.author | Rengifo-Pardo, Monica | |
dc.contributor.author | Barraza, Pedro Pablo | |
dc.contributor.author | Jiménez Hernàndez, Dennys | |
dc.contributor.author | González Coba, Andrés | |
dc.contributor.author | De La Hoz Mendoza, Katya | |
dc.contributor.author | Bethony, Jeffrey M. | |
dc.contributor.author | Simon, Gary L. | |
dc.date.accessioned | 2018-09-04T16:50:51Z | |
dc.date.available | 2018-09-04T16:50:51Z | |
dc.date.issued | 2018-08 | |
dc.description.abstract | Zika virus infection has been associated with the development of a spectrum of neurologic disease including Guillain–Barré syndrome (GBS)1. GBS is an autoimmune disorder of the peripheral nervous system often triggered by a preceding infection. The mechanism of Zika-associated GBS (Z-GBS) and the long-term clinical course is unknown. The purpose of this study was to describe the 2-year clinical course of Z-GBS in order to provide further insights into disease pathogenesis and prognosis. | eng |
dc.identifier.issn | 22221751 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12442/2237 | |
dc.language.iso | eng | eng |
dc.publisher | Springer | eng |
dc.rights.accessrights | info:eu-repo/semantics/openAccess | |
dc.rights.license | Licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional | eng |
dc.source | Emerging Microbes & Infections | eng |
dc.source | Vol. 7, No.148 (2018) | eng |
dc.source.uri | https://www.nature.com/articles/s41426-018-0151-9 | eng |
dc.subject | Zika-Virus | eng |
dc.subject | Guillain-Barre Syndrome | eng |
dc.subject | Chinkungunya infection | eng |
dc.subject | Epidemiology | eng |
dc.subject | Infectious disease control | eng |
dc.subject | Respiratory infections | eng |
dc.title | Long-term clinical outcomes of Zikaassociated Guillain-Barré syndrome | eng |
dc.type | article | eng |
dcterms.references | Parra, B. et al. Guillain–Barré syndrome associated with Zika virus infection in Colombia. N. Engl. J. Med. 375, 1513–1523 (2016). | eng |
dcterms.references | Hughes, R. A. et al. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 130, 2245–2257 (2007). | eng |
dcterms.references | Rees, J. H., Soudain, S. E., Gregson, N. A. & Hughes, R. A. Campylobacter jejuni infection and Guillain–Barré syndrome. N. Engl. J. Med. 333, 1374–1379 (1995). | eng |
dcterms.references | Islam, B. et al. Guillain-Barré syndrome following varicella-zoster virus infection. Eur. J. Clin. Microbiol Infect. Dis. 37, 511–518 (2018). | eng |
dcterms.references | Cao-Lormeau, V. et al. Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 10027, 1531–1539 (2016). | eng |
dcterms.references | Arias, A. et al. Guillain-Barré syndrome in patients with a recent history of Zika in Cucuta, Colombia: a descriptive case series of 19 patients from December 2015 to March 2016. J. Crit. Care. 37, 19–23 (2017). | eng |
dcterms.references | Anaya, J. et al. A comprehensive analysis and immunobiology of autoimmune neurological syndromes during the Zika virus outbreak in Cúcuta, Colombia. J. Autoimmun. 77, 123–138 (2017). | eng |
dcterms.references | Hughes, R. A. & Cornblath, D. R. Guillain-Barre syndrome. Lancet 366, 1653–1666 (2005). | eng |
dcterms.references | Griffin, J. et al. Pathology of the motor‐sensory axonal Guillain‐Barré syndrome. Ann. Neurol. 39, 17–28 (1996). | eng |
dcterms.references | Sejvar, J. J. et al. Guillain–Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 29, 599–612 (2011). | eng |
dcterms.references | Dowd, K. A. et al. Broadly neutralizing activity of Zika virus-immune sera identifies a single viral serotype. Cell Rep. 16, 1485–1491 (2016). | eng |
dcterms.references | Frenzen, P. D. Economic cost of Guillain-Barre syndrome in the United States. Neurology 71, 21–27 (2008). | eng |
dcterms.references | Wolfe, F., Michaud, K. & Pincus, T. Development and validation of the health assessment questionnaire II: a revised version of the health assessment questionnaire. Arthritis Rheumatol. 50, 3296–3305 (2004). | eng |